🇺🇸 FDA
Patent

US 9895448

Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

granted A61KA61K47/545A61K47/549

Quick answer

US patent 9895448 (Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARBUTUS BIOPHARMA CORPORATION
Grant date
Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K47/545, A61K47/549, A61K47/551, A61K47/554